← Issue №13/ week of Sep 27, 2026/IBD

The Effect of Antifungal Therapy on Disease Activity in Patients with Inflammatory Bowel Disease: A Retrospective Matched Analysis.

From GI Signals issue №13: what this paper found, what it changes, and where it sits against the current standard of care, reviewed by Simon Mathews, MD.

IBD retrospective · n=229 · Sep 22, 2026 · Clin Transl Gastro · IF 3.4

The Effect of Antifungal Therapy on Disease Activity in Patients with Inflammatory Bowel Disease: A Retrospective Matched Analysis.

New evidenceCrohn's diseaseulcerative colitisbiologics
Clinical takeawayDo not withhold fluconazole for candidiasis in IBD patients due to concerns about worsening disease activity.
What it foundFluconazole did not increase relapse rate in IBD patients in remission (HR 0.85, 95% CI 0.27-2.6) or delay remission in those with active disease (HR 0.68, 95% CI 0.33-1.4).
ContextConfirms that antifungal therapy does not adversely affect IBD disease course, addressing a common clinical concern.
No standard claimed for this paper

Every paper is compared to the standard governing its question. This one is not: either no standard in the corpus matches it, or the comparison did not hold up on review and was withdrawn rather than published unverified. Both are logged.

Chen S … Jangi S · Clinical and Translational Gastroenterology · IF 3.4 · PubMed ↗Permalink
← Read the whole of issue №13 Every paper GI Signals surfaces gets a page like this one. All issues